Synergy among antibacterial peptides and between peptides and small-molecule antibiotics

References

• Serra P, Brandimarte C, Martino P, Carlone S, Giunchi G. Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies. Arch. Intern. Med.137(11), 1562–1567 (1977).
   PubMedGoogle Scholar
• Valerius NH, Koch C, Holby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet338(8769), 725–726 (1991).
   PubMed Web of Science ®Google Scholar
• Otvos L Jr, de Olivier Inacio V, Wade JD, Cudic P. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob. Agents Chemother.50(9), 3146–3149 (2006).
   PubMed Web of Science ®Google Scholar
• Mor A, Hani K, Nicolas P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J. Biol. Chem.269(50), 31635–31641 (1994).
   PubMed Web of Science ®Google Scholar
• Singh PK, Tack BF, McCray PB, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquids. Am. J. Physiol. Lung Cell. Mol. Physiol.279(5), 799–805 (2000).
   PubMed Web of Science ®Google Scholar
• Otvos L Jr. Antibacterial peptides isolated from insects. J. Pept. Sci.6(10), 497–511 (2000).
   PubMed Web of Science ®Google Scholar
• Levy O, Oi CE, Weiss J, Lehrer RI, Elsbach P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J. Clin. Invest.94(2), 672–682 (1994).
   PubMed Web of Science ®Google Scholar
• Matsuzaki K, Mitani Y, Akada KY et al. Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa. Biochemistry37(43), 15144–15153 (1988).
   Google Scholar
• Westerhoff HV, Zasloff M, Rosner JL et al. Functional synergism of the magainins PGLa and magainin-2 in Escherichia coli, tumor cells and liposomes. Eur. J. Biochem.228(2), 257–264 (1995).
   PubMedGoogle Scholar
• Luders T, Birkemo GA, Fimland G, Nissen-Meyer J, Nes IF. Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria. Appl. Environ. Microbial.69(3), 1797–1799 (2003).
   PubMed Web of Science ®Google Scholar
• Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin. Microbiol. Infect.6(12), 690–691 (2000).
   PubMed Web of Science ®Google Scholar
• Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother.53(5), 2133–2135 (2009).
   PubMed Web of Science ®Google Scholar
• Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob.5, 10 (2006).
   PubMedGoogle Scholar
• Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymixin B against meropenem-resistant Acinetobacter baumannii using Etest and time–kill assays. Diagn. Microbiol. Infect. Dis.63(2), 228–232 (2009).
   PubMed Web of Science ®Google Scholar
• Dufour M, Simmonds RS, Bremer PJ. Development of a method to quantify in vitro the synergistic activity of ‘natural’ antimicrobials. Int. J. Food Microbiol.85(3), 249–258 (2003).
   PubMedGoogle Scholar
• Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother.52(1), 333–336 (2008).
   PubMed Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi Y et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother.63(3), 534–542 (2009).
   PubMed Web of Science ®Google Scholar
• Hindler J, Hochstein L, Howell A. Preparation of routine media and reagents used in antimicrobial susceptibility testing. In: Clinical Microbiology Practical HandBook Antimicrobial Susceptibility Testing. Section-5. Hindler J (Ed). American Society for Microbiology, Washington, DC, USA (2002).
   Google Scholar
• Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii : a comparison with Etest, time–kill, and checkerboard methods. Diagn. Microbiol. Infect. Dis.38(1), 43–50 (2000).
   PubMed Web of Science ®Google Scholar
• Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J. Chemother.16(3), 282–287 (2004).
   PubMed Web of Science ®Google Scholar
• Cirioni O, Silvestri C, Ghiselli R et al. Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides27(11), 2600–2606 (2006).
   PubMedGoogle Scholar
• Cirioni O, Silvestri C, Ghiselli R et al. Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother.62(6), 1332–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Otvos L Jr. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci.11(11), 697–706 (2005).
   PubMed Web of Science ®Google Scholar
• Szabo D, Ostorhazi E, Binas A et al. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int. J. Antimicrob. Agents35(4), 357–361 (2010).
   PubMedGoogle Scholar
• Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant Acinetobacter baumannii : promising therapeutic options for treatment of infections with colistin-resistant strains. Clin. Infect. Dis.45(5), 594–598 (2007).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulphamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis.44(3), 259–263 (2002).
   PubMed Web of Science ®Google Scholar
• Cirioni O, Giacometti A, Silvestri C et al.In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. Antimicrob. Agents Chemother.50(11), 3923–3925 (2006).
   PubMedGoogle Scholar
• Cirioni O, Giacometti A, Kamysz W et al.In vitro activities of tachiplesin III against Pseudomonas aeruginosa. Peptides28(4), 747–751 (2007).
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni O, Kamysz W et al.In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1–7)M(2–9)NH2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. Diagn. Microbiol. Infect. Dis.49(3), 197–200 (2004).
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni O, Kamysz W et al.In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. Int. J. Antimicrob. Agents26(3), 235–240 (2005).
   PubMed Web of Science ®Google Scholar
• Ulvatne H, Karoliussen S, Stiberg T, Rekdal O, Svendsen J. Short antibacterial peptides and erythromycin act synergistically against Escherichia coli. J. Antimicrob. Chemother.48(2), 203–208 (2001).
   PubMedGoogle Scholar
• Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob. Chemother.44(5), 641–645 (1999).
   PubMed Web of Science ®Google Scholar
• Mangoni ML, Rinaldi AC, Di Giulio A et al. Structure–function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur. J. Biochem.267(5), 1447–1454 (2000).
   PubMedGoogle Scholar
• Cudic M, Condie BA, Weiner DJ et al. Development of novel antibacterial peptides that kill resistant isolates. Peptides23(12), 2071–2083 (2002).
   PubMedGoogle Scholar
• Cassone M, Vogiatzi P, La Montagna R et al. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3–APO, alone or in synergy with conventional antibiotics. Peptides29(11), 1878–1886 (2008).
   PubMedGoogle Scholar
• Tan TY, Ng LSY, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother.60(2), 421–423 (2007).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interacitons of colistin and rifampicin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis.40(3), 117–120 (2001).
   PubMed Web of Science ®Google Scholar
• Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother.41(4), 494–495 (1998)
   PubMed Web of Science ®Google Scholar
• Credito K, Lin G, Koeth L, Sturgess MA, Appelbaum PC. Activity of levofloxacin alone and in combination with a DnaK inhibitor against Gram-negative rods, including levofloxacin-resistant strains. Antimicrob. Agents Chemother.53(2), 814–817 (2009).
   PubMed Web of Science ®Google Scholar
• Brumfitt W, Salton MRJ, Hamilton-Miller JMT. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Stephylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother.50(5), 731–734 (2002).
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni O, Del Prete MS, Paggi AM, D’Errico MM, Scalise G. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Peptides21(8), 1155–1160 (2000).
   PubMedGoogle Scholar
• Easton DM, Nijnik A, Mayer ML, Hancock RE. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol.27(10), 582–590 (2009).
   PubMed Web of Science ®Google Scholar
• Magliani W, Conti S, Cunha RL, Travassos LR, Polonelli L. Antibodies as crypts of antiinfective and antitumor peptides. Curr. Med. Chem.16(18), 2305–2323 (2009).
   PubMedGoogle Scholar
• Polonelli L, Ponton J, Elguezabal N et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One3(6), e2371 (2008).
   PubMed Web of Science ®Google Scholar
• Rozgonyi F, Szabo D, Kocsis B et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr. Med. Chem.16(30), 3996–4002 (2009).
   PubMedGoogle Scholar
• Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr. Opin. Microbiol.7(5), 466–476 (2004).
   PubMed Web of Science ®Google Scholar
• Noto PB, Abbadessa G, Cassone M et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci.17(7), 1249–1255 (2008).
   PubMedGoogle Scholar
• Dartois V, Sanchez-Quesada J, Cabezas E et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother.49(8), 3302–3310 (2005).
   PubMed Web of Science ®Google Scholar
• Deslouches B, Islam K, Craigo JK et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother.49(8), 3208–3216 (2005).
   PubMed Web of Science ®Google Scholar
• Ge Y, MacDonald DL, Holroyd KJ et al.In vitro properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother.43(4), 782–788 (1999).
   PubMed Web of Science ®Google Scholar
• Cassone M, Frith N, Vogiatzi P et al. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. Int. J. Pept. Res. Ther.15(2), 121–128 (2009).
   Google Scholar
• Otvos L Jr. Peptide-Based Drug Design. Methods in Molecular Biology. Volume 494. Humana Press, NJ, USA (2008).
   Google Scholar
• Ostorhazi E, Rozgonyi F, Szabo D et al. Intramuscularly administered peptide A3–APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers (2010) (In Press).
   Google Scholar
• Yan H, Hancock REW. Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob. Agents Chemother.45(5), 1558–1560 (2001).
   PubMed Web of Science ®Google Scholar
• Patrzykat A, Zhang L, Mendoza V, Iwama GK, Hancock REW. Synergy of histone-derived peptides of coho salmon with lysozyme and flounder pleurocydin. Antimicrob. Agents Chemother.45(5), 1337–1342 (2001).
   PubMed Web of Science ®Google Scholar
• Graham S, Coote PJ. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J. Antimicrob. Chemother.59(4), 759–762 (2007).
   PubMed Web of Science ®Google Scholar
• Fehri LF, Wroblewski H, Blanchard A. Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis. Antimicrob. Agents Chemother.51(2), 468–474 (2007).
   PubMedGoogle Scholar
• Giacometti A, Cirioni O, Del Prete MS et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J. Antimicrob. Chemother.46(5), 807–810 (2000).
   PubMedGoogle Scholar
• Giacometti A, Cirioni O, Barchiesi F, Scalise G. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn. Microbiol. Infect. Dis.38(2), 115–118 (2000).
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni O, Del Prete MS et al.In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas malophilia. Antimicrob. Agents Chemother.44(6), 1716–1719 (2000).
   PubMedGoogle Scholar